Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Elecoglipron Reference Formulation Dose A · 1 trial · 1 indication
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
To evaluate the PK of different formulations of elecoglipron following single oral administration in healthy participants.
| Arm | Type | Description |
|---|---|---|
| Cohort 1-Treatment Sequence A | EXPERIMENTAL | Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose A) in Period 2. |
| Cohort 1 - Treatment Sequence B | EXPERIMENTAL | Participant will receive a single dose of elecoglipron test formulation 1 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2. |
| Cohort 2 - Treatment Sequence C | EXPERIMENTAL | Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 1 (Dose B) in Period 2. |
| Cohort 2 - Treatment Sequence D | EXPERIMENTAL | Participant will receive a single dose of elecoglipron test formulation 1 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2. |
| Cohort 3 - Treatment Sequence E | EXPERIMENTAL | Participant will receive a single dose of elecoglipron reference formulation (Dose A) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose A) in Period 2. |
| Cohort 3 - Treatment Sequence F | EXPERIMENTAL | Participant will receive a single dose of elecoglipron test formulation 2 (Dose A) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose A) in Period 2. |
| Cohort 4 - Treatment Sequence G | EXPERIMENTAL | Participant will receive a single dose of elecoglipron reference formulation (Dose B) in Period 1 followed by a single dose of elecoglipron test formulation 2 (Dose B) in Period 2. |
| Cohort 4 - Treatment Sequence H | EXPERIMENTAL | Participant will receive a single dose of elecoglipron test formulation 2 (Dose B) in Period 1 followed by a single dose of elecoglipron reference formulation (Dose B) in Period 2. |
| Name | Type | Description |
|---|---|---|
| Elecoglipron Reference Formulation Dose A | DRUG | Elecoglipron tablets will be administered orally. |
| Elecoglipron Test formulation 1 Dose A | DRUG | Elecoglipron tablets will be administered orally. |
| Elecoglipron Reference Formulation Dose B | DRUG | Elecoglipron tablets will be administered orally. |
| Elecoglipron Test formulation 1 Dose B | DRUG | Elecoglipron tablets will be administered orally. |
| Elecoglipron Test formulation 2 Dose A | DRUG | Elecoglipron tablets will be administered orally. |
| Elecoglipron Test formulation 2 Dose B | DRUG | Elecoglipron tablets will be administered orally. |
Inclusion Criteria: * Healthy participants with suitable veins for cannulation or repeated venipuncture. * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. * Females of childbearing potential must not be lactating and if heterosexually ac...
Elecoglipron Reference Formulation Dose A is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, with an ongoing trial evaluating the relative bioavailability and safety of different oral formulations of elecoglipron. The drug is not approved and remains under investigation.
Elecoglipron Reference Formulation Dose A is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting a Phase 1 clinical trial to investigate the drug's relative bioavailability and safety in healthy participants.
Elecoglipron Reference Formulation Dose A is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is currently recruiting participants and aims to evaluate the relative bioavailability and safety of different oral formulations of elecoglipron.
Elecoglipron Reference Formulation Dose A is being studied in a single Phase 1 clinical trial with the identifier NCT07723833. The trial, titled 'A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants,' is currently recruiting in the United States and has an enrollment target of 152 participants.
Elecoglipron Reference Formulation Dose A is a specific formulation of the investigational drug elecoglipron. The Phase 1 trial NCT07723833 is designed to compare the relative bioavailability and safety of different oral formulations of elecoglipron, with Elecoglipron Reference Formulation Dose A being one of the formulations under evaluation.